Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Could Add To Its Hospital-Acquired Infection Portfolio With Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed acquisition of NeuTec would give Novartis two Phase III therapies for its nosocomial arsenal.

You may also be interested in...



Novartis Halts Development Of Antibiotic Booster Acquired In NeuTec Deal

Drug maker will take a $235 million charge in the third quarter as a result.

Novartis Halts Development Of Antibiotic Booster Acquired In NeuTec Deal

Drug maker will take a $235 million charge in the third quarter as a result.

EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb

Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel